Baseline characteristics of the overall patient population
| Characteristics . | 8-day Ven (n = 14) . | 11-day Ven (n = 9) . | 14-day Ven (n = 11) . | All cohorts (N = 34) . |
|---|---|---|---|---|
| Age, median (range), y | 54 (27-69) | 57 (43-71) | 59 (42-71) | 59 (27-71) |
| Sex (male), n (%) | 8 (57) | 6 (67) | 5 (45) | 19 (56) |
| Race, n (%) | ||||
| White | 7 (50) | 3 (33.3) | 3 (27.3) | 13 (38.2) |
| Non-White | 7 (50) | 6 (66.7) | 8 (72.7) | 21 (61.8) |
| WBC at diagnosis, median (range), ×103/μL | 20.6 (1.6-223.6) | 3.4 (1.4-343.6) | 15.2 (1.2-241.7) | 16.4 (1.2-343.6) |
| WBC on day 1, median (range), ×103/μL | 4.6 (1.3-22.3) | 4.7 (1.7-24.4) | 2 (0.7-24.1) | 4 (0.7-24.4) |
| Secondary AML, n (%) | 3 (21) | 1 (11) | — | 4 (11.7) |
| Cytogenetic risk, n (%) | ||||
| Favorable | 2 (14) | 2 (22) | 1 (9) | 5 (14.7) |
| Intermediate | 7 (50) | 6 (67) | 7 (64) | 20 (58.8) |
| Adverse | 5 (36) | 1 (11) | 3 (27) | 9 (26.5) |
| ELN 2022 risk, n (%) | ||||
| Favorable | 5 (36) | 4 (44) | 4 (36) | 13 (38.2) |
| Intermediate | 1 (7) | 2 (22) | 3 (27) | 6 (17.7) |
| Adverse | 8 (57) | 3 (33) | 4 (36) | 15 (44.1) |
| Molecular subtypes | ||||
| NPM1 | 4 (28) | 3 (33) | 6 (54) | 13 (38.2) |
| FLT3 ITD | 2 (14) | 2 (22) | 3 (27) | 7 (20.6) |
| TP53 | 3 (21) | 1 (11) | 1 (9) | 5 (14.7) |
| Characteristics . | 8-day Ven (n = 14) . | 11-day Ven (n = 9) . | 14-day Ven (n = 11) . | All cohorts (N = 34) . |
|---|---|---|---|---|
| Age, median (range), y | 54 (27-69) | 57 (43-71) | 59 (42-71) | 59 (27-71) |
| Sex (male), n (%) | 8 (57) | 6 (67) | 5 (45) | 19 (56) |
| Race, n (%) | ||||
| White | 7 (50) | 3 (33.3) | 3 (27.3) | 13 (38.2) |
| Non-White | 7 (50) | 6 (66.7) | 8 (72.7) | 21 (61.8) |
| WBC at diagnosis, median (range), ×103/μL | 20.6 (1.6-223.6) | 3.4 (1.4-343.6) | 15.2 (1.2-241.7) | 16.4 (1.2-343.6) |
| WBC on day 1, median (range), ×103/μL | 4.6 (1.3-22.3) | 4.7 (1.7-24.4) | 2 (0.7-24.1) | 4 (0.7-24.4) |
| Secondary AML, n (%) | 3 (21) | 1 (11) | — | 4 (11.7) |
| Cytogenetic risk, n (%) | ||||
| Favorable | 2 (14) | 2 (22) | 1 (9) | 5 (14.7) |
| Intermediate | 7 (50) | 6 (67) | 7 (64) | 20 (58.8) |
| Adverse | 5 (36) | 1 (11) | 3 (27) | 9 (26.5) |
| ELN 2022 risk, n (%) | ||||
| Favorable | 5 (36) | 4 (44) | 4 (36) | 13 (38.2) |
| Intermediate | 1 (7) | 2 (22) | 3 (27) | 6 (17.7) |
| Adverse | 8 (57) | 3 (33) | 4 (36) | 15 (44.1) |
| Molecular subtypes | ||||
| NPM1 | 4 (28) | 3 (33) | 6 (54) | 13 (38.2) |
| FLT3 ITD | 2 (14) | 2 (22) | 3 (27) | 7 (20.6) |
| TP53 | 3 (21) | 1 (11) | 1 (9) | 5 (14.7) |
WBC, white blood cells.